Pfizer Inc. Stock
€26.07
Your prediction
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | -0.870% | 9.441% | 7.452% | -25.135% | 0.824% | -19.118% | -24.322% |
| Biogen Inc. | 0.290% | 1.539% | 8.287% | -28.446% | -13.274% | -9.151% | -1.088% |
| Elanco Animal Health Inc. | 0.310% | 27.487% | 10.165% | 84.653% | 16.228% | -41.843% | - |
| AbbVie Inc. | -0.190% | -2.034% | -4.601% | 11.403% | 6.552% | 56.939% | 112.771% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance, the financials of Pfizer Inc. (NYSE: PFE) appear to be strong, showcasing a robust position in the pharmaceuticals industry. As a prominent player, Pfizer has consistently demonstrated growth in its total assets and revenue, laying the foundation for a favorable outlook on the company's performance. As we dive deeper into the financial statements, it becomes essential to analyze the pros and cons to acquire a comprehensive understanding of Pfizer's financial health and future potential.
*Pros: *
Growing Total Assets and Shareholders' Equity: The company's total assets have grown consistently over the past three years, from approximately €154.2 billion in 2020 to €181.5 billion in 2021, and reaching a notable USD 197.2 billion in 2022. Such growth indicates strong financial management and an increased capacity to generate income. Similarly, the total stockholder equity has also risen, reflecting the company's ability to create value for its shareholders.
Comments
News
2 No-Brainer Dividend Stocks to Buy in May
Dividends may be boring but are essential to building a well-balanced portfolio. After all, dividend payments have accounted for approximately 85% of the S&P 500's total returns since 1960, per a
This 6% Yielding Dividend Stock Could Pump Up Your Passive-Income Stream
After steadily raising its payout by 163% over the past 15 years, Pfizer (NYSE: PFE) continues to be one of the most reliable pharma stocks an income-seeking investor can reach for these days. The
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Healthcare doesn't get the hype that other industries -- say, technology -- get. However, there arguably isn't an industry more important to humankind's well-being. That's especially true in the